Key opinion leaders (KOLs) interviewed by GlobalData have expressed the need for therapies with higher efficacy to improve ...

Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Abbvie's stock rises 4.51% despite looming trade tensions and competitive pressures. Analysts from Morgan Stanley, Raymond ...

AbbVie’s Skyrizi tallied the most TV impressions among pharma brands in July, rising from second in June. The psoriasis treatment achieved a share of voice (SOV) of 4.61% with 2.5 billion impressions.

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in ...

ROCKVILLE, MD, USA I August 7, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for ...

Gedeon Richter, Hungary’s biggest drugmaker, aims to clinch more deals like its partnership with AbbVie Inc. to expand in the US without being weighed down by import tariffs imposed by President ...

North Chicago, Illinois-based AbbVie Inc. has shown a robust performance despite market fluctuations. While the broader ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...